156. Rett syndrome Clinical trials / Disease details
Clinical trials : 44 / Drugs : 61 - (DrugBank : 23) / Drug target genes : 57 - Drug target pathways : 83
| No. | TrialID | Date_ enrollment | Date_ registration | Public_title | Scientific_title | Condition | Intervention | Primary_ sponsor | Secondary_ sponsor | Recruitment_ Status | Inclusion_ agemin | Inclusion_ agemax | Inclusion_ gender | Target_ size | Phase | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | EUCTR2015-004448-20-GB (EUCTR) | 28/11/2016 | 23/09/2016 | Sarizotan: Treatment in patients with Rett Syndrome with Respiratory Symptoms. | A Randomized, Double-Blind, Placebo-Controlled, Six-Month Study to Evaluate the Efficacy, Safety and Tolerability of Sarizotan in Patients with Rett Syndrome with Respiratory Symptoms | Rett syndrome MedDRA version: 20.0;Level: LLT;Classification code 10039000;Term: Rett's disorder;System Organ Class: 100000004850;Therapeutic area: Diseases [C] - Congenital, Hereditary, and Neonatal Diseases and Abnormalities [C16] | Product Name: sarizotan hydrochloride Product Code: EMD 128130 INN or Proposed INN: sarizotan hydrochloride Other descriptive name: SARIZOTAN HYDROCHLORIDE Product Name: sarizotan hydrochloride Product Code: EMD 128130 INN or Proposed INN: sarizotan hydrochloride Other descriptive name: SARIZOTAN HYDROCHLORIDE Product Name: sarizotan hydrochloride Product Code: EMD 128130 INN or Proposed INN: sarizotan hydrochloride Other descriptive name: SARIZOTAN HYDROCHLORIDE | Newron Pharmaceuticals S.p.A. | NULL | Not Recruiting | Female: yes Male: yes | 129 | Phase 2 | United States;Australia;Italy;United Kingdom;India |